As mentioned above, while anti-TNF have been associated with positive treatment outcomes mainly in inflammatory LBP, whereas anti-NGF monoclonal antibodies are strong analgesics, JAK inhibitors might offer a balanced combination of these two effects. This evidence concerns the gene NGF and Low back pain.